Abstract
Seventy-five aztreonam treatment courses in 74 patients with gram-negative septicemia resulted in 56 clinical cures (75%), 12 partial clinical cures (16%), and 7 clinical failures (9%). Eradication of the original pathogen from the blood was obtained in all patients but two, who had relapses 1 and 4 days, respectively, after treatment. In nine patients (12%) a superinfection was reported. Significant adverse reactions were limited to one transient urticarial rash. Aztreonam may prove to be an effective alternative for the treatment of gram-negative septicemia, but superinfections should be carefully monitored.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chandrasekar P. H., Smith B. R., LeFrock J. L., Carr B. Enterococcal superinfection and colonization with aztreonam therapy. Antimicrob Agents Chemother. 1984 Aug;26(2):280–282. doi: 10.1128/aac.26.2.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenberg R. N., Reilly P. M., Luppen K. L., McMillian R., Bollinger M., Wolk S. M., Darji T. B., Noorani A. A. Treatment of serious gram-negative infections with aztreonam. J Infect Dis. 1984 Nov;150(5):623–630. doi: 10.1093/infdis/150.5.623. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Labthavikul P. In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents. Antimicrob Agents Chemother. 1983 Aug;24(2):227–232. doi: 10.1128/aac.24.2.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Percival A., Thomas E., Hart C. A., Karayiannis P. In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):49–55. doi: 10.1093/jac/8.suppl_e.49. [DOI] [PubMed] [Google Scholar]
- Phillips I., King A., Shannon K., Warren C. SQ 26,776: in-vitro antibacterial activity and susceptibility to beta-lactamases. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):103–110. doi: 10.1093/jac/8.suppl_e.103. [DOI] [PubMed] [Google Scholar]
- Romero-Vivas J., Rodríguez-Créixems M., Bouza E., Hellín T., Guerrero A., Martínez-Beltrán J., García de la Torre M. Evaluation of aztreonam in the treatment of severe bacterial infections. Antimicrob Agents Chemother. 1985 Aug;28(2):222–226. doi: 10.1128/aac.28.2.222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sykes R. B., Cimarusti C. M., Bonner D. P., Bush K., Floyd D. M., Georgopapadakou N. H., Koster W. M., Liu W. C., Parker W. L., Principe P. A. Monocyclic beta-lactam antibiotics produced by bacteria. Nature. 1981 Jun 11;291(5815):489–491. doi: 10.1038/291489a0. [DOI] [PubMed] [Google Scholar]
- Van Laethem Y., Husson M., Klastersky J. Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Aug;26(2):224–227. doi: 10.1128/aac.26.2.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Hancox J. SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):39–47. doi: 10.1093/jac/8.suppl_e.39. [DOI] [PubMed] [Google Scholar]